<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125276</url>
  </required_header>
  <id_info>
    <org_study_id>NL79129.018.21</org_study_id>
    <nct_id>NCT05125276</nct_id>
  </id_info>
  <brief_title>Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients</brief_title>
  <acronym>LEGACY</acronym>
  <official_title>Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces&#xD;
      the risk of stent thrombosis, myocardial infarction and stroke after coronary stent&#xD;
      implantation. Inevitably, it is also associated with a higher risk of (major) bleeding. Given&#xD;
      the advances in stent properties, stenting implantation technique and pharmacology, it may be&#xD;
      possible to treat patients with a single antiplatelet strategy completely omitting aspirin.&#xD;
&#xD;
      Objective: This study will assess whether omitting aspirin reduces the rate of major or minor&#xD;
      bleeding while remaining non-inferior to the current standard of care with regards to net&#xD;
      clinical adverse events and ischemic events in patients with non-ST segment elevation acute&#xD;
      coronary syndrome.&#xD;
&#xD;
      Study design: Open-label, multicentre randomized controlled trial.&#xD;
&#xD;
      Study population: Adult patients presenting with non-ST segment elevation acute coronary&#xD;
      syndrome planned for percutaneous coronary intervention.&#xD;
&#xD;
      Intervention: In the intervention group aspirin will be completely omitted from the&#xD;
      antiplatelet regimen in the 12 months following PCI.&#xD;
&#xD;
      Main study parameters/endpoints: The primary net adverse clinical endpoint is defined as the&#xD;
      composite of all-cause death, myocardial infarction, stroke and Bleeding Academic Research&#xD;
      Consortium type 3 or 5 bleeding at 12 months. The primary bleeding endpoint is major or minor&#xD;
      bleeding defined as Bleeding Academic Research Consortium type 2, 3 or 5 bleeding at 12&#xD;
      months. The primary ischemic endpoint is ischemic events defined as the composite of&#xD;
      all-cause death, myocardial infarction and stroke at 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net adverse clinical endpoint (NACE)</measure>
    <time_frame>12 months</time_frame>
    <description>The primary net adverse clinical endpoint at 12 months is the composite of all-cause mortality, myocardial infarction, stroke and major bleeding defined as Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The primary bleeding endpoint at 12 months is major or minor bleeding defined as BARC type 2, 3 or 5 bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ischemic endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The primary ischemic endpoint at 12 months is the composite of all-cause mortality, myocardial infarction and stroke</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3090</enrollment>
  <condition>Non ST Segment Elevation Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Interventional arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin (75-100 mg once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No aspirin</intervention_name>
    <description>No aspirin</description>
    <arm_group_label>Interventional arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>75-100 mg once daily</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients presenting with NSTE-ACS planned for PCI&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or contraindication for aspirin or P2Y12-inhibitors&#xD;
&#xD;
          -  Concurrent use of oral anticoagulants (e.g. because of atrial fibrillation)&#xD;
&#xD;
          -  Overwriting indication for DAPT (e.g. recent PCI or ACS)&#xD;
&#xD;
          -  Planned surgical intervention within 12 months of revascularization&#xD;
&#xD;
          -  Pregnant or breastfeeding women at time of enrolment&#xD;
&#xD;
          -  Participation in another trial with an investigational drug or device (i.e. stent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.P.S Henriques</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

